---
layout: default
title: Lisinopril Dihydrate
parent: 僅模型預測 (L5)
nav_order: 211
evidence_level: L5
indication_count: 0
---

# Lisinopril Dihydrate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Lisinopril Dihydrate: Drug Repurposing Evaluation — Awaiting Complete Data

## One-Sentence Summary

Lisinopril dihydrate is a registered pharmaceutical product in Malaysia with 3 active market authorizations, confirmed by NPRA records.
However, the current Evidence Pack is **critically incomplete**: no TxGNN repurposing predictions have been generated, and both the mechanism of action and approved indication details are absent.
This report documents the current data state and outlines the mandatory steps before a full repurposing evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not retrieved from current data |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (No predictions yet — model pipeline not yet run) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN repurposing predictions are currently available for lisinopril dihydrate. The query log confirms that DrugBank was queried successfully and returned 1 result, but the DrugBank ID was not populated in the dataset. Without a valid DrugBank ID, the knowledge graph (KG) and deep learning (DL) prediction pipelines cannot identify candidate new indications — this is the root cause of the empty `predicted_indications` field.

The mechanism of action (MOA) is likewise flagged as a high-severity data gap. Without MOA information, it is impossible to assess whether lisinopril's pharmacological pathway is mechanistically relevant to any candidate indication, which is a prerequisite for any scientifically defensible repurposing claim.

In addition, the 3 NPRA license records were retrieved in terms of count, but all structured fields (authorization numbers, product names, dosage forms, approved indications) are unpopulated, making it impossible to establish even the currently approved therapeutic scope in Malaysia. All substantive analysis is therefore deferred until these gaps are resolved.

---

## Malaysia Market Information

NPRA records confirm 3 active registrations for lisinopril dihydrate in Malaysia. Detailed license information was not captured in the current data pull and must be retrieved in the next cycle.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|----------------------|--------------|-------------|---------------------|
| Not retrieved | Not retrieved | Not retrieved | Not retrieved |
| Not retrieved | Not retrieved | Not retrieved | Not retrieved |
| Not retrieved | Not retrieved | Not retrieved | Not retrieved |

---

## Safety Considerations

Please refer to the package insert for complete safety information. Package insert warnings, contraindications, and drug interaction data were not retrieved in this cycle and are required before any safety screening can be performed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is missing the two most critical inputs for a repurposing evaluation — TxGNN predictions and approved indication details — making it impossible to assess either the scientific plausibility or the regulatory landscape for any new indication at this time.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Retrieve the NPRA/TFDA package insert for lisinopril dihydrate: download the product monograph PDF and extract warnings and contraindications to enable safety pre-screening
- **[High — DG002]** Map the confirmed DrugBank query result to a DrugBank ID in the dataset, then retrieve the full MOA entry to support mechanistic plausibility analysis
- **[Required]** Re-run the TxGNN KG and DL prediction pipelines with the correct DrugBank ID to populate `predicted_indications`
- **[Required]** Retrieve complete NPRA registration details for all 3 licenses — authorization numbers, product names, dosage forms, and approved indications
- **[Final step]** Regenerate the Evidence Pack (v5+) and re-issue this evaluation report once all the above data gaps are resolved
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

